Premium
Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa
Author(s) -
Wendt S.,
Whybra C.,
Kampmann C.,
Teichmann E.,
Beck M.
Publication year - 2005
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-005-0018-9
Subject(s) - enzyme replacement therapy , fabry disease , medicine , pregnancy , disease , multisystem disease , alpha galactosidase , lysosomal storage disease , pediatrics , surgery , biology , genetics
Summary Fabry disease is an inherited lysosomal storage disease caused by deficiency of α‐galactosidase A. Enzyme replacement therapy for this multisystem progressive disease has been available only since 2001. We here report the first known successful pregnancy of a female patient receiving such therapy.